U.S., Dec. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07266428) titled 'A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors' on Nov. 16.
Brief Summary: The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects that it may cause. The trial will also see if OTP-01 causes tumors to shrink and how the body processes OTP-01 by measuring drug levels in the blood.
The main questions this study aims to answer are:
* What is the recommended dose of OTP-01 for adults with solid tumors?
* Is OTP-01 safe and tolerable?
* Does OTP-0...